General Information of Drug (ID: DMUNL5Q)

Drug Name
N-benzyl-4-bromo-3-(morpholinosulfonyl)benzamide Drug Info
Synonyms
CHEMBL475493; Cambridge id 5211146; AC1LL0O9; Oprea1_380259; N-benzyl-4-bromo-3-(morpholinosulfonyl)benzamide; CBDivE_007294; SCHEMBL5623492; MolPort-002-316-866; BDBM50277135; AKOS008461950; MCULE-3410949273; AB00075261-01; SR-01000198591; SR-01000198591-1
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
1076739
TTD Drug ID
DMUNL5Q

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Guanfacine extended release DMB1CZ8 Attention deficit hyperactivity disorder 6A05.Z Approved [2]
NABILONE DMVRYT2 Insomnia 7A00-7A0Z Approved [3]
GW-42004 DMY3KSU Lipid metabolism disorder 5C52.Z Phase 2 [4]
KHK-6188 DMF6CTI Neuropathic pain 8E43.0 Phase 2 [5]
LY-2828360 DMO8IEZ Pain MG30-MG3Z Phase 2 [5]
APD371 DM3XT5V Crohn disease DD70 Phase 2 [6]
S-777469 DMZGNOJ Atopic dermatitis EA80 Phase 2 [7]
842166X DMOV0AP Pain MG30-MG3Z Phase 2 [8]
Beta-caryophyllene DM7583A Pain MG30-MG3Z Phase 2 [9]
Vicasinabin DMF16CU Diabetic retinopathy 9B71.0 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cannabinoid receptor 2 (CB2) TTMSFAW CNR2_HUMAN Inhibitor [1]

References

1 CB2 selective sulfamoyl benzamides: optimization of the amide functionality. Bioorg Med Chem Lett. 2009 Jan 15;19(2):309-13.
2 Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory. Neurobiol Learn Mem. 2008 Sep;90(2):374-81.
3 Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
4 Company report (Gwpharm)
5 Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands. Current Medicinal Chemistry . 10/2013; 21(2).
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs. 2009 Mar;14(1):165-79.
8 The agonist binding mechanism of human CB2 receptor studied by molecular dynamics simulation, free energy calculation and 3D-QSAR studies. Yao Xue Xue Bao. 2013 Sep;48(9):1436-49.
9 The cannabinoid CB1 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. Eur Neuropsychopharmacol. 2014 Apr;24(4):608-20.
10 Clinical pipeline report, company report or official report of Roche